Significant Ownership of ASTRAZENECA PLC
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for ASTRAZENECA PLC focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Matthew Bowden - Matthew Bowden / Company Secretary
- Manager location
- Cambridge
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow ASTRAZENECA PLC and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
CIK context first
Continue from ASTRAZENECA PLC
Significant Ownership of ASTRAZENECA PLC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| CLLS | Cellectis S.A. | Ordinary shares, nominal value of EUR0.05 per ordinary share | 44% | $66,440,000 | 44,000,000 | AstraZeneca PLC | 23 Jan 2025 | ||
| Innate Pharma SA | Ordinary Shares, EUR0.05 nominal value per share | 8.3% | 7,825,501 | AstraZeneca PLC | 22 Dec 2025 | ||||
| MNPR | Monopar Therapeutics Inc. | Common Stock, $0.001 par value per share | 7.8% | $34,126,392 | 522,667 | AstraZeneca PLC | 31 Dec 2025 | ||
| CDT | Conduit Pharmaceuticals Inc. | Common Stock, par value $0.0001 per share | 1.1% | $3,340 | 73,892 | AstraZeneca PLC | 31 Mar 2025 |
Schedules 13D/G Reported by ASTRAZENECA PLC:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.